<DOC>
	<DOCNO>NCT00933452</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetics duloxetine hydrochloride tablet Chinese Han Healthy Subjects . The single oral dose multiple oral dose drug body effect different dosage drug also evaluate .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Duloxetine Chinese Han Healthy Subjects</brief_title>
	<detailed_description>This open , parallel assignment ( low-dose , moderate-dose high-dose ) , inpatient , sequential-group pharmacokinetics study single oral administer multiple oral administer healthy Chinese male female subject single investigational site . All subject Chinese Han race . Approximately 36 healthy male female Chinese subject participate study . One half subject enrol dose group female . Twelve subject enrol 3 dose level group . Safety evaluate self-reported adverse event , schedule physical examination , vital sign , 12-lead ECGs , clinical laboratory test result . Single-dose blood sample ( 5 mL ) obtain within 2 hour test article administration 1 , 2 , 3 , 4 , 5 , 6 , 8 , 12 , 15 , 24 , 36 , 48 , 72 hour test article administration . Multiple-dose ( subject moderate dose group finish first step single-dose 30mg trial , one week later , repeatedly administer duloxetine 30 mg 7days ) blood sample ( 5 mL ) obtain 4th , 5th , 6th 7th day test article administration ( test valley concentration ) 1 , 2 , 3 , 4 , 5 , 6 , 8 , 12 , 15 , 24 , 36 , 48 , 72 hour last test article administration ( 7th day ) . Cross-over ( subject high dose group finish first step single-dose 60 mg generic duloxetine trial , one week later , administer single-dose innovator duloxetine 60 mg ) blood sample obtain first step .</detailed_description>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Healthy Chinese Han male female determine investigator basis medical history physical examination Age 18 45 year old screening Body mass index ( BMI ) 19~24 kg/m2 body weight â‰¥ 50 kg screen Normal clinical laboratory test result 'no clinical significantly abnormal ' result judge investigator screen Subjects comply requirement study accord study procedure A sigh date ICF ( informed consent form ) approval IEC Participation drug trial within 1 month prior enrollment study Known hypersensitivity duloxetine hydrochloride relative compound Abnormal 12lead electrocardiogram ( ECG ) result increase risk participate study determine investigator Presence history medical disorder , include cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematologic , psychiatric neurologic system , medical condition would significantly affect absorption , distribution , metabolism , excretion investigational drug , increase risk administer investigational drug , interfere explanation data History hepatitis B and/or HBsAg ( + ) Serum HIV antibody ( + ) hepatitis C Antibody ( + ) Female subject childbearing potential positive human chorionic gonadotropin ( HCG ) test lack reliable method contraception History blood donor within 3 month prior enrollment History drug abuse alcoholism Use drug include traditional Chinese Medicine within 1 week prior enrollment Any unsuitable subject judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>duloxetine</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>antidepressant</keyword>
	<keyword>antidepressive agent</keyword>
	<keyword>depression</keyword>
	<keyword>psychotropic drug</keyword>
	<keyword>safety</keyword>
	<keyword>Chinese</keyword>
	<keyword>HAN</keyword>
	<keyword>BDNF</keyword>
</DOC>